STOCKHOLM, July 27, 2018 /PRNewswire/ -- Second quarter
- Revenue increased by 13.8% to €161.1m (€141.6m). Organic revenue grew by 13.7%.
- Operating profit amounted to €6.4m (€5.7m), representing an operating margin of 4.0% (4.0%).
- Net profit amounted to €7.0m (€2.3m), which represents a net profit margin of 4.3% (1.6%).
- Cash flow from operating activities amounted to €7.3m (€8.9m).
- Basic/diluted earnings per share (EPS) were €0.050 (€0.016).
- EBITDA increased by 10.7% to €13.5m (€12.2m), corresponding to an EBITDA margin of 8.4% (8.6%).
First half
- Revenue increased by 13.9% to €323.0m (€283.5m). Organic revenue grew by 14.0%.
- Net profit amounted to €16.4m (€6.7m), which represents a net profit margin of 5.1% (2.4%).
- EBITDA increased by 12.2% to €28.5m (€25.4m), corresponding to an EBITDA margin of 8.8% (9.0%).
REVENUE AND EARNINGS
€ millions (€m) |
Q2 2018 |
Q2 2017 |
Growth |
6M 2018 |
6M 2017 |
Growth |
FY 2017 |
Revenue |
161.1 |
141.6 |
14% |
323.0 |
283.5 |
14% |
580.2 |
Operating profit |
6.4 |
5.7 |
12% |
14.5 |
12.5 |
16% |
28.8 |
Operating profit margin, % |
4.0% |
4.0% |
4.5% |
4.4% |
5.0% |
||
Net profit |
7.0 |
2.3 |
204% |
16.4 |
6.7 |
145% |
20.2 |
Net profit margin, % |
4.3% |
1.6% |
5.1% |
2.4% |
3.5% |
||
Earnings per share, € |
0.050 |
0.016 |
213% |
0.117 |
0.054 |
117% |
0.157 |
Diluted earnings per share, € |
0.050 |
0.016 |
213% |
0.117 |
0.054 |
117% |
0.157 |
EBITDA |
13.5 |
12.2 |
11% |
28.5 |
25.4 |
12% |
55.0 |
EBITDA margin, % |
8.4% |
8.6% |
8.8% |
9.0% |
9.5% |
For Alternative Performance Measure definitions and reconciliations, refer to note 7.
This information is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8.00 (CEST) on 27 July 2018. This interim report and other information about Medicover, is available at medicover.com.
For further information, please contact:
Paula Treutiger
Corporate Communications & Investor Relations, Director
Phone: +46-73-66 6599
Mail: paula.treutiger@medicover.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medicover/r/interim-report-april-june-2018,c2582213
The following files are available for download:
Interim report April-June 2018 |
Share this article